Compare Fiverr International Ltd (FVRR) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Gilead Sciences, Inc. — how do they compare? Fiverr International Ltd trades at $8.74 (market cap $314.57M), while Gilead Sciences, Inc. trades at $135.64 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 535.2× Fiverr International Ltd's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals.
| FVRR | GILD | |
|---|---|---|
Market Cap | $314.57M | $168.35B |
Sector | Industrials | Health |
52-Week High | $26.67 | $155.80 |
52-Week Low | $8.75 | $110.56 |
Enterprise Value | $66.95M | $191.42B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $8.71, down 4.18% over 24 hours, reflecting bearish technical signals and recent earnings misses. The stock shows attractive valuation multiples with a P/E of 10.8 and P/S of 0.77, while revenue grew to $430.91M in 2025. However, Q2 2026 results missed expectations, with revenue declining 10% year-over-year due to AI disruption pressures, as reported by MarketBeat on July 29, 2026.
The outlook remains cautious with significant AI-related headwinds compressing demand for freelance services. Near-term risks include execution challenges in a shifting competitive landscape, but the current low valuation may offer contrarian appeal if the company successfully adapts its strategy.
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
